Neural correlates of working memory training in HIV patients: study protocol for a randomized controlled trial by unknown
STUDY PROTOCOL Open Access
Neural correlates of working memory
training in HIV patients: study protocol for
a randomized controlled trial
L Chang1*, GC Løhaugen2,3, V Douet1 , EN Miller4, J Skranes2,3 and T Ernst1
Abstract
Background: Potent combined antiretroviral therapy decreased the incidence and severity of HIV-associated
neurocognitive disorders (HAND); however, no specific effective pharmacotherapy exists for HAND. Patients with
HIV commonly have deficits in working memory and attention, which may negatively impact many other cognitive
domains, leading to HAND. Since HAND may lead to loss of independence in activities of daily living and negative
emotional well-being, and incur a high economic burden, effective treatments for HAND are urgently needed. This
study aims to determine whether adaptive working memory training might improve cognitive functions and neural
network efficiency and possibly decrease neuroinflammation. This study also aims to assess whether subjects with
the LMX1A-rs4657412 TT(AA) genotype show greater training effects from working memory training than TC(AG)
or CC(GG)-carriers.
Methods/Design: 60 HIV-infected and 60 seronegative control participants will be randomized to a double-blind
active-controlled study, using adaptive versus non-adaptive Cogmed Working Memory Training® (CWMT), 20–25
sessions over 5–8 weeks. Each subject will be assessed with near- and far-transfer cognitive tasks, self-reported
mood and executive function questionnaires, and blood-oxygenation level-dependent functional MRI during
working memory (n-back) and visual attention (ball tracking) tasks, at baseline, 1-month, and 6-months after CWMT.
Furthermore, genotyping for LMX1A-rs4657412 will be performed to identify whether subjects with the TT(AA)-
genotype show greater gain or neural efficiency after CWMT than those with other genotypes. Lastly, cerebrospinal
fluid will be obtained before and after CWMT to explore changes in levels of inflammatory proteins (cytokines and
chemokines) and monoamines.
Discussion: Improving working memory in HIV patients, using CWMT, might slow the progression or delay the
onset of HAND. Observation of decreased brain activation or normalized neural networks, using fMRI, after CWMT
would lead to a better understanding of how neural networks are modulated by CWMT. Moreover, validating the
greater training gain in subjects with the LMX1A-TT(AA) genotype could lead to a personalized approach for future
working memory training studies. Demonstrating and understanding the neural correlates of the efficacy of CWMT
in HIV patients could lead to a safe adjunctive therapy for HAND, and possibly other brain disorders.
Trial registration: ClinicalTrial.gov, NCT02602418.
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Background
The incidence of HIV-associated dementia has declined
dramatically since the introduction of potent combined
antiretroviral therapy; however, milder forms of HIV-
associated neurocognitive disorders (HAND) persist.
Some 30 to 50 % of HIV-infected individuals have HAND,
which is more prevalent in those older than 50 years
[1, 2]. Other co-morbidities, such as substance abuse
(e.g., alcohol, cannabis, or psychostimulants) and hepa-
titis C infection, further exacerbate or hasten the devel-
opment of HAND, partly owing to poorer medication
adherence compared with those without HAND [3, 4].
With an increasing proportion of HIV-infected individ-
uals at risk of HAND, which leads to both functional
and occupational disabilities, the development of effect-
ive treatments or adjunctive therapy for these patients is
critical.
The current therapy for HIV infection leaves a ‘thera-
peutic gap’ for HAND [1, 2]. Combined antiretroviral
therapy is effective at suppressing the viral burden but
cannot reverse HAND completely or prevent the devel-
opment of HAND, even in those with long-standing
aviremia [5]. In addition, antiretroviral drugs may have
adverse or neurotoxic effects on the brain [6–8]. A num-
ber of pharmacological trials, including trials of minocy-
cline [9], CEP-1347 [10], memantine [11], lithium [12],
peptide T [13], and selegiline [14–16], were conducted
with no clear efficacy for cognitive improvements, al-
though some of these studies demonstrated positive ef-
fects on neuroimaging measures in human beings or
immunohistochemistry in animal models. Therefore, no
evidence-based treatment is available to improve the
cognitive function of patients with HAND. In addition,
neuropathological, neuroimaging, and cerebrospinal
fluid studies consistently showed ongoing aberrant neu-
roinflammation, with persistent glial activation [17], and
lesser dopamine transporters [18, 19]; both may contrib-
ute to brain injury and HAND in HIV patients. Hence,
effective treatment for HAND might require a multi-
modal approach.
Another important reason to develop an effective
treatment is that HAND leads to higher healthcare costs.
For instance, a study of patients with HIV or AIDS in a
community-based clinic in Canada found that the care
for those with a neuropsychiatric disorder was more
costly, both immediately before and after the diagnosis,
regardless of the specific neuropsychiatric diagnosis [20].
Likewise, an Australian study showed that with the pre-
dicted doubling of HIV infection in men and tripling in
women over the next two decades, the cost of care could
nearly double at the current 7 % prevalence of HIV-
associated dementia, primarily for residential care [21].
Another study from Sweden on the pharmacoeconomics
of mild cognitive impairment showed that postponing
the development of dementia even for a few years after
diagnosis of mild cognitive impairment would result in
cost savings of approximately $5,300 per person [22].
Therefore, an effective treatment for HAND or to delay
the onset of HAND, even in a subset of HIV-infected in-
dividuals, might lead to significant cost savings.
The major cognitive domains affected in HAND are
attention and working memory [23, 24], in both visual
and verbal domains [25–28]. Working memory is de-
fined as the cognitive skill to retain and manipulate in-
formation ‘online’ over short periods of time. Working
memory is thus necessary for concentration and main-
taining awareness and is crucial for learning and execu-
tive functions, such as reasoning and planning. Working
memory is also needed in daily life in all settings. Hence,
deficits in working memory may negatively affect many
other cognitive domains. While the introduction of com-
bined antiretroviral therapy led to generally improved
neuropsychological function, working memory dysfunc-
tion was not improved or was even exacerbated with on-
going infection [1, 29]. Working memory dysfunction in
HIV has major consequences, such as being a strong
predictor of unemployment and dependence in activities
of daily living [30], self-reported cognitive complaints
[31], and poorer medication adherence [32, 33]. There-
fore, enhancing working memory ability and delaying
progression of working memory decline should benefit
HIV-infected individuals.
Importantly, working memory skills can be trained, for
instance, using Cogmed Working Memory Training®
(CWMT), a computer-based adaptive working memory
training program that is effective for improving cogni-
tion. The efficacy of CWMT was first demonstrated in
children with attention deficit hyperactivity disorders
[34], who showed better non-verbal and verbal working
memory performance and improved response inhibition
and reasoning, as well as reduced parent-rated inatten-
tive symptoms of attention deficit hyperactivity disorders
[35]. Patients with traumatic brain injury also had im-
proved functioning in daily life activities, which was
maintained even 6 months after CWMT [36]. Other
populations who benefitted from CWMT included
stroke victims [37], adolescents born preterm with ex-
tremely low birth weight [38], children with cochlear im-
plants [39], and healthy older persons [40]. However,
this remarkably safe and innovative intervention has not
been evaluated as an adjunctive therapy for HAND.
To our knowledge, no study has investigated the
neural correlates of working memory training in HIV
patients, or whether neural networks might re-organize
or show corresponding improved neural efficiency.
Working memory deficits in HIV patients probably in-
volve injuries to the frontostriatal circuits, which are
brain regions that have been shown in neuropathological
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studies [41] to be preferentially affected in HIV patients.
Working memory deficits have been observed in encod-
ing [23], reaction times [42], and simultaneous short-
term storage and processing [43], suggesting subcortical
deficits as well as abnormalities of the prefrontal cortex
[26]. The brain is highly ‘plastic’ in that brain activities
and network connections can change quickly and that
changes can last for a long time after a task is practiced,
as found in tasks involving visual attention [44], object
naming [45], motor learning [46, 47], and working mem-
ory [48–50]. Blood-oxygenation level-dependent func-
tional magnetic resonance imaging (BOLD-fMRI)
studies following 5-weeks of adaptive CWMT showed
increased training-related activity in the medial frontal
gyrus and parietal cortices for the trained tasks [51, 52]
and in the the inferior frontal gyrus for the untrained
tasks with varied working memory load [52]. However,
compared with fixed low-level training (active control
condition), older adults who received adaptive working
memory training showed decreased brain activation in
frontal, parietal, and temporal cortices but increased ac-
tivity in the caudate and thalamus [53]. Transfer of per-
formance improvement (gain) to untrained tasks
(transfer of gain) requires overlapping networks and
brain regions common to both tasks, especially the stri-
atum [54]. Our proposed fMRI studies will further assess
brain changes associated with improvements on working
memory and other cognitive tasks.
Recent data also indicate that individuals with different
genotypes for dopamine-related genes may have differ-
ent training gain, such as polymorphisms in LMX1A
[55] and catechol-O-methyltransferase Val158Met [56].
This study will focus on LMX1A, which encodes for the
protein LIM homeobox transcription factor 1 alpha, a
positive regulator of insulin gene transcription, but is
also involved in the proliferation, differentiation, and
maintenance of dopamine-producing neurons in the
midbrain [57–59]. Polymorphisms in LMX1A were asso-
ciated with dopaminergic disorders, such as Parkinson’s
disease [60] and schizophrenia [61], and, recently, with
the effects of working memory training [55]. Specifically,
subjects with TT(AA) alleles at the LMX1A-rs4657412
had greater training-related gains in verbal working
memory than those with heterozygous TC(AG) or
CC(GG) alleles [55]. Since HIV patients commonly
showed dopaminergic deficits, with decreased dopamine
transporters [18, 19] and decreased cerebrospinal fluid
dopamine and dopamine metabolites [62], we will
explore whether genetic variations of LMX1A-rs4657412
modulates working memory training effects and cerebro-
spinal fluid monoamines and their metabolites in our
subjects.
Based on this prior knowledge, the current study has
three major aims and one exploratory aim.
 Aim 1: To perform a double-blind active-controlled
study on the effectiveness of CWMT (25 sessions
over 5–8 weeks) in HIV-infected and seronegative
subjects, with or without cognitive deficits, and
assess whether the training will improve cognitive
functioning (on working memory and some
non-trained tasks that require working memory) at
1 month (to assess gain) and 6 months (to assess
maintenance of gain) after the training.
 Aim 2: To assess the neural correlates of working
memory training, and determine whether brain
activation will improve, at 1 month and 6 -months
after the training, as assessed by functional MRI
(fMRI) during working memory and attention tasks.
 Aim 3: Since individuals with the TT(AA) genotype
for the single nucleotide polymorphism LMX1A-
rs4657412 had greater magnitude of training-related
gains in verbal working memory [55], we will assess
our subjects for the allelic variations on training
results (gain and maintenance).
Exploratory aim
We will explore changes in neuroinflammatory markers,
and monoamine and their metabolites in the cerebro-
spinal fluid before and at least 1 month after CWMT,
and evaluate the relationships between cerebrospinal
fluid markers, cognitive performance, and BOLD-fMRI
signals.
Methods/design
The proposed study uses a 2 × 2 repeated-measures ana-
lysis of covariance (ANCOVA) design to evaluate the ef-
fects of 5 weeks of CWMT, adaptive versus ‘active
control (fixed low level)’ training, as assessed by the im-
provement index (generated from task performances
within the CWMT), neurocognitive testing, BOLD-fMRI
measurements, cerebrospinal fluid neuroinflammatory
proteins, monoamine, and metabolite levels. We propose
to enroll 60 HIV-infected individuals and 60 seronega-
tive healthy participants, with 30 adaptive and 30 active-
control-training subjects randomized in each group
(Fig. 1). HIV-positive and seronegative subject groups
will be matched by age, sex, education, socioeconomic
status, and cognitive status (matched by global cognitive
score from the seven cognitive domains tested), as well
as other co-variates (e.g., nicotine smoking and other
substances abused). Based on the initial screening evalu-
ations, subjects who fulfill all study criteria will be
scheduled for a baseline neuropsychological evaluation,
MRI-fMRI scans, and a lumbar puncture.
Primary and secondary outcome measures
The main goal of this study is to examine the effective-
ness of intensive adaptive working memory training for
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the treatment of HAND. The primary outcome mea-
sures will be the improvement index on CWMT, im-
provement on non-trained near-transfer working
memory tasks, and changes on brain activation assessed
with BOLD-fMRI during working memory and attention
tasks. Secondary contrasts will evaluate genotype effects
(LMX1A, TT(AA) versus TC(AG) or CC(GG)) on cogni-
tive improvements and BOLD-fMRI. We will also assess
CWMT-related improvements on self-reported depres-
sive and various psychopathological symptoms, using the
Center for Epidemiological Studies–Depression Scale
Revised and Symptom Checklist–90 revised items, and
on self-rated functionality, using the Independent Activ-
ity of Daily Living assessment and the Behavior Rating
Inventory of Executive Function–Adult Version.
Participants
Subjects will be recruited via flyers, referrals from local
HIV clinics, by word of mouth, or from ongoing studies.
Potential research subjects will be screened by telephone
or on-site, before being scheduled for a detailed out-
patient evaluation at the UH-QMC MR Research Center
at the Queen’s Medical Center in Honolulu, Hawaii.
In our pilot studies, we observed effect sizes from 0.7 to
1.2 for pre versus post CWMT in HIV-positive subjects in
four of the working memory tests. We will need to en-
roll ≈ 17 HIV-positive subjects to detect an effect size of
0.7 for 80 % power (two-sided test). Effect sizes for BOLD
signal change (pre versus post adaptive CWMT (0 and 1-
back)) were 0.58–1.5 in the pilot HIV-positive subjects; at
least 26 HIV-positive subjects are needed to detect an ef-
fect size of 0.58 for 80 % power (two-sided test). Since we
encountered an ≈ 15 % (13 % in HIV and 20 % in the sero-
negative group) attrition rate in our pilot study, we
propose to enroll 30 HIV and 30 seronegative subjects per
training group to ensure adequate power, for a total of 120
subjects (60 HIV, 60 seronegative). Based on our experi-
ence, we will have to screen ≈ 500 individuals initially by
telephone and 200 of these potentially eligible participants
in person to have ≈ 150 subjects who will fulfill our study
criteria, and complete the baseline evaluation. We expect
that only ≈ 120 subjects (60 HIV and 60 seronegative) will
follow through and be randomized for the training. We
also expect that only 85 % (n = 102, 50 HIV and 52 sero-
negative) will return for the 1 month follow-up and only
80 % of these (n = 86, 40 HIV and 42 seronegative) will re-
turn to complete the 6-month follow-up evaluations. Fur-
thermore, we expect that ≈ 20 participants who completed
the ‘active control’ training will want to continue with the
‘adaptive training’ (Fig. 1).
Fig. 1 Study design. We plan to screen ≈ 500 individuals initially by telephone and 200 of these potentially eligible participants in person, to
identify ≈ 150 subjects who will fulfill our study criteria, and complete the baseline evaluation. We expect that only ≈ 120 (60 HIV and 60
seronegative) will follow through and be randomized for the training. We also expect that only 85 % (n = 102, 50 HIV, and 52 seronegative) will
return for the 1 month follow-up and only 80 % of these (n = 86, 40 HIV, and 42 seronegative) will return to complete the 6-month follow-up
evaluations. Furthermore, we expect that ≈ 20 participants who completed the ‘active control’ training will want to continue with the ‘adaptive
training’. CSF, cerebrospinal fluid; I/E, inclusion or exclusion; MR, magnetic resonance; SN, seronegative; WM, working memory.
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HIV-infected participants must meet the following in-
clusion criteria: (1) men or women of any ethnicity,
ages ≥ 18 years and able to provide informed consent; (2)
HIV seropositive (with documentation from medical re-
cords); (3) stable on an antiretroviral regimen for
6 months or will remain without antiretroviral treatment
during the duration of the CWMT study.
Seronegative healthy participants must meet the fol-
lowing inclusion criteria: (1) men or women of any eth-
nicity, ages ≥ 18 years and able to give informed consent;
(2) seronegative for HIV (to be confirmed by an HIV
ELISA blood test if screened positive with ClearView®
COMPLETE HIV-1/2 test).
Exclusion criteria for all subjects are: (1) history of co-
morbid psychiatric illness that might confound the ana-
lysis of the study (e.g., schizophrenia, obsessive-
compulsive disorder, major depression, or bipolar
disorder); (2) confounding neurological disorder (e.g.,
multiple sclerosis, Parkinson’s disease, non-HIV brain
infections, neoplasms, cerebral palsy, or significant head
trauma with loss of consciousness >30 minutes); (3) sig-
nificantly abnormal screening laboratory tests (>2 stand-
ard deviations) that might indicate a chronic medical
condition (e.g., diabetes, severe cardiac, renal or liver
disorders) that might affect brain function; (4) medica-
tions that could significantly alter functional brain im-
aging studies; (5) current or history of drug dependence
within the previous 2 years, including amphetamines,
cocaine, alcohol, and opiates, according to DSM-V de-
pendency criteria (past casual or recreational usage will
not be excluded); (6) positive urine toxicology screen
(methamphetamine, amphetamine, cocaine, marijuana,
benzodiazepine, barbiturates, and opiates except for false
positive tests due to medications) on day of neuro-
psychological testing or fMRI studies; (7) pregnancy (to
be verified by urine pregnancy test in women of child-
bearing age); (8) inability to read at an 8th-grade level
(to be verified by the Wechsler Test of Adult Reading);
(9) other contraindications for MRI studies, such as me-
tallic or electronic implants in the body (e.g., pacemaker,
surgical clips, or pumps), or severe claustrophobia.
Baseline assessments
We will first explain the study to each subject and obtain
oral and written consent. The study design, experiments,
and consent forms were approved by the institutional re-
view board of the University of Hawaii at Manoa
(CHS#20523). A detailed medical and drug use history
and physical and neuropsychiatric evaluations will be
performed, along with screening blood tests to assess
general health, including complete blood cell count,
chemistry panel, thyroid function tests, hepatitis C and
HIV serology. An electrocardiogram will be obtained to
screen for significant cardiac abnormalities; subjects will
be referred for further cardiac evaluations should signifi-
cant abnormalities be found. Psychiatric and quality-of-
life evaluations will be additionally performed through a
battery of questionnaires and self-reported assessments;
some will be repeated after training (Table 1).
Subjects with significant psychiatric symptoms will be
further assessed by a qualified physician, to determine
whether psychiatric referral is necessary. Those with sui-
cidal thoughts or acute intoxication will be sent to the
psychiatric emergency department. Subjects with signifi-
cant medical problems, screening blood test abnormal-
ities, or electrocardiographic abnormalities will be
referred to their primary care physicians, other clinics or
the emergency department as needed.
Neuropsychological evaluation
The 2 hour long neuropsychological test battery is de-
signed to detect deficits in (1) working memory and at-
tention, which implicate networks in frontal and parietal
regions; (2) decision making and inhibition, which in-
volve primarily the anterior cingulate and orbitofrontal
cortices; and (3) motor and psychomotor speed, which
are associated with alterations in the basal ganglia and
cerebellum.
1. Diagnosis of HAND or HAND-equivalent at baseline
will be determined using z-scores from seven
cognitive domains, adjusted for age and education,
and derived from our existing normative database
(including ≈ 450 healthy seronegative controls tested
with the same protocol). HAND classification will be
made according to the Updated Research Nosology
for HAND [63] by physicians for all subjects. The
HIV-positive and seronegative control groups will be
matched by their cognitive status (i.e., global
z-score) (Table 2).
2. General intelligence: the Wechsler Test of Adult
Reading will provide an estimate of premorbid
intellectual functioning during our screening
procedure to ensure that the subjects have a verbal
intelligence quotient > 80 and can provide consent.
The Wechsler Adult Intelligence Scale IV will be
used to evaluate general cognitive ability
(intelligence quotient) for all subjects at baseline.
3. Assessments of changes in working memory, other
cognition and function (primary outcomes) will be
administered repeatedly at baseline, 1 month after
training (either adaptive working memory or ‘active
control’ training condition), and 6 months after the
adaptive working memory training. Alternative word
lists or stories will be used for repeated testing.
Table 2 shows the tests involved in the trained
working memory tests, which will include the ‘start
index, maximum index, and improvement index’, the
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non-trained working memory tests and the transfer
of working memory capacity gain to other cognitive
functions.
For the non-trained working memory tasks, no prac-
tice effects are expected [64]. However, for the other
neuropsychological tests, variable degrees of practice ef-
fects will occur with test–retest [65]; we will control for
such practice effects by performing the same tests before
and after CWMT in both HIV-positive and seronegative
control subjects.
Cognitive intervention using Cogmed® RM
The Cogmed® RM (Table 3) was developed for school-
aged children; however, we chose this version for our
adult participants since it is more colorful and appealing
to the participants than the adult version (Cogmed®
QM). The training program consists of 25 training ses-
sions (minimum of 20 required), 30–40 minutes per day,
4–5 days per week over a 5–8 week period [35]. Subjects
will perform either the ‘active control’, with a fixed low
level across each task, or an ‘adaptive’ version, with in-
creasing difficulty for the working memory tasks. The
training will be performed either in the participants’
homes, or at the research laboratory. We will ensure that
participants have high-speed internet access. Subjects
will be trained using verbal and non-verbal working
memory tasks that involve: (1) maintenance of several
stimuli at the same time; (2) short delays during which
the representation of stimuli should be held in the work-
ing memory; (3) unique sequencing of stimulus order in
each trial. Training will be supplemented with weekly
guidance by trained ‘coaches’, who can review subjects’
progress online and will telephone them to give feed-
back, motivation, and advice to optimize their training
experience.
Participant randomization
Individuals meeting all study criteria will be randomized,
with 30 participants assigned to each training condition
to maintain a balanced design. Randomization to study
condition will be stratified across characteristics that
might affect outcomes. Stratification variables include
age, sex (male, female), and severity of cognitive deficits
(based on the global cognitive z-score). This random as-
signment will ensure that both the participant and the
Table 1 Questionnaires and interviews




Hollingshead Four Factor Index [90] Socioeconomic status; combination of race, ethnicity,
occupational status and education level
✓
Psychiatric assessments
Symptom Checklist–90–revised Psychological and emotional distress ✓ ✓ ✓
Center for Epidemiological Studies–
Depression Scale [91]




Substance Abuse Subtle Screening
Inventory-3 [92]
Identification of individuals with a high probability
of having a substance use disorder
✓ ✓ ✓
Urine toxicology Substance usage ✓ ✓ ✓
Quality-of-life assessments
Independent Activity of Daily Living [93] Ability to carry out daily functions ✓ ✓ ✓
Behavior Rating Inventory of Executive
Function–Adult Version
Executive function ✓ ✓ ✓
Pittsburgh Sleep Quality Index [94], Epworth
Sleepiness Scale [95]
General level of daytime sleepiness ✓ ✓ ✓
PROMIS® Global health status and pain intensity, interference
and behavior
✓ ✓ ✓
Medical Outcomes Study HIV Health Survey [96] Health status for HIV-positive patients ✓ ✓ ✓
World Health Organization Quality of Life [97] Well-being and quality of life ✓ ✓ ✓
Biospecimens
Blood DNA and genotyping ✓
Blood and serum Cytokines and monoamines and neurometabolite
measurements
✓ ✓ ✓
Cerebrospinal fluid Cytokines monoamines and neurometabolite
measurements
✓ ✓
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‘coaches’ (who will monitor the subjects online and by
phone) for the training will be blinded to the training
being used. No other members of the study team (except
for the principal investigator) or participants will be in-
formed of which condition assignment has been made.
The randomization assignment will remain blinded until
1 month after the training and the follow-up visit are
complete. Subjects who were trained on the active con-
trol (low-level training) condition will then be offered
the opportunity to be trained on the intensive adaptive
working memory training (open-label phase), and will be
followed-up again at 1 month and 6 months after the
adaptive training. Subjects unable to participate in the
open-label phase during this period will be given the op-
tion to continue participation after the active control 6-
month follow-up. The data manager will maintain the
records that link specific participant identification num-
bers to study conditions, and assignment codes. This
information will be available for the principal investiga-
tor in case there is any need to break the study blind for
a specific participant while the individual is still in the
study.
MRI
All participants will undergo a series of MRI sessions be-
fore, and 1-month and 6-months after CWMT. All
structural and fMRI studies will be performed on a
research-dedicated 3 Tesla Siemens TIM Trio scanner
(VB17), using a 12-channel phase-array head coil.
Structural MRI
A 3D magnetization-prepared rapid gradient-echo scan
will be performed (sagittal, TE/TR/TI = 4.9 ms/2.2 s/1 s,
7° flip angle, 1 mm resolution covering the whole-brain).
Next, a 3D-T2-weighted sequence (SPACE) will be ac-
quired (sagittal, TR/TE = 3200/447 ms, field of view =
Table 2 Neuropsychological assessments (non-trained working memory tests)





Paced Auditory Serial Addition Test ✓
Wechsler Adult Intelligence Scale IV (Digit Span, Letter
Number Sequencing, Arithmetic, and Digit-Symbol Coding)
✓ ✓ ✓
California Computerized Assessment Package ✓ ✓ ✓
Delis–Kaplan Executive Function System ✓ ✓ ✓
Abstraction, executive functions
Stroop Color Interference Test ✓
Trail Making Test Part B ✓
Fluency
Controlled Oral Word Association Test (FAS) ✓
Design Fluency Tests (Ruff Figural Fluency) ✓
Memory
Rey Auditory Verbal Learning Test Delayed Recall ✓ ✓ ✓
Rey Osterrieth Complex Figure Test ✓ ✓ ✓
Speed of information processing, psychomotor speed
Symbol Digit Modalities Test ✓
Trail Making Test Part A ✓
Motor skills
Grooved pegboard test (dominant and non-dominant hand) ✓
Verbal, language
Wechsler Adult Intelligence Scale, fourth edition, verbal comprehension index ✓
Wechsler Test of Adult Reading ✓
Wechsler Adult Intelligence Scale ✓
Wechsler Memory Scale IV
Spatial span ✓ ✓ ✓
Visual, verbal immediate and long-term memory ✓ ✓ ✓
Mental control ✓ ✓ ✓
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320 mm, 1.0 × 1.0 × 1.0 mm resolution, 192 slices, gener-
alized autocalibrating partially parallel acquisitions
(GRAPPA) = 2, 3:52 min). Both scans will be reviewed to
screen for possible brain lesions or structural
abnormalities.
BOLD-fMRI
The entire brain is scanned continuously with an axial
single-shot gradient-echo echo planar imaging sequence
(TE/TR30/2500 ms, 20 cm field of view, 64 × 64 reso-
lution, ≈35 × 3 mm slices, no gap) with motion correc-
tion. An electronic pulse from the scanner synchronizes
the fMRI scan and stimulus presentation. Scans with
excess motion (more than ±1 mm translations or ±1° ro-
tations) are repeated immediately.
fMRI paradigms
Each subject will perform six different tasks during the
fMRI scans. Tasks will be displayed using a binocular
video display (Nordic Neurolab Inc.™). Subjects will be
trained first outside the scanner to ensure that they will
be able to perform the tasks well during the scans
(>80 % accuracy, monitored during the scan). Scans with
unacceptable response accuracy will be repeated
immediately.
Working memory (n-back)
This task uses a block design (30 s of alternating control
and activation periods, including 3 s of instruction).
During activation periods, a random sequence of single
letters is presented (1 letter per second for 500 ms). Sub-
jects are trained to press a button whenever the current
letter is identical to the letter 1 or 2 events back, or for
any number (0-back). The targets (i.e., 0-, 1-, or 2-back
events) are random events (5/30 s block). Button events
are used to determine accuracy and reaction times. Dur-
ing control periods, subjects passively view a random se-
quence of symbols (non-letters), with matching font size,
brightness, and timing.
Visual attention (ball tracking)
These tasks evaluate non-verbal visual attention [66, 67],
which we also expect to improve after working memory
training. Subjects mentally track two, three, or four tar-
get balls that are highlighted briefly among 10 randomly
moving, colliding balls. Every 12.5 s, another set of balls
is highlighted for 1 s and the subjects push a button if
subjects agreed that the balls were the original targets
(performance monitoring). Periods of tracking (1 min)
alternate with passive viewing (1 min) of balls that move
in the same random motion without highlighting (block
design: 1 min/period × 2 periods × 3 blocks).
Table 3 Description of the 12 modules in Cogmed® Working Memory Training
Task Description
Verbal working memory (with visuospatial components)
Input module
(numbers)
A panel with 1 to 9 is shown. Numbers are presented aurally and light up on the panel sequentially.
Participants then have to click on the numbers in the reversed sequence.
Input module with lid
(hidden numbers)
Same as previous task, except numbers are presented aurally only, since they are covered by a lid, which
opens when all the numbers are read.
Stabilizer (letters) A circle of lamps is shown. A sequence of letters is presented aurally along with specific lamps that light up. Participants
are then presented with a letter in the middle of the circle, and have to click on the lamp that lit up.
Decoder Letters are read sequentially along with a lamp that lights up. The participant then has to reproduce the sequence
by selecting one letter from three possible letters below each lamp.
Visuospatial working memory
Visual data link (grid) Lamps light up sequentially in a 4 × 4 grid, and the participant must reproduce the sequence by clicking on the lamps
in the same order afterwards.
Rotating data link
(rotating grid)
Same as the grid task above, except that after the lamps light up, the entire board rotates 90° and the participant has
to click on the sequence of lamps in the rotated grid.
Data room
(three-dimensional grid)
Lamps will light up sequentially in a three-dimensional box (view from the front), with four lamps per plane, and the
participant must reproduce the sequence by clicking on the lamps.
Three-dimensional
cube
The program zooms in on different planes of a cube (four squares on the back and two squares on the other planes)
as they light up sequentially. The participant must click the squares in the correct order.
Rotating (rotating dot) Lamps light up sequentially on a circle, which rotates slowly clockwise, and the participant has to reproduce the
sequence by clicking on the lamps on the moving circle.
Sorter Boxes open to reveal numbers out of order and the participant must click on the boxes in the correct numerical order.
Asteroids Asteroids light up sequentially while moving around the screen and the participant must reproduce the sequence by
clicking on the moving asteroids.
Space whack Craters emit puffs of smoke sequentially. The participant must remember the order that the puffs appeared, in order
to click on the alien that will pop out of the crater in the same sequence.
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Genotyping
Samples of DNA will be extracted from whole blood or
saliva collected in EDTA-tubes using DNeasy Blood &
Tissue Kit (catalog number 69506, Qiagen Inc., Valencia,
CA, USA). Genomic DNA will be subjected to restric-
tion fragment length polymorphism PCR to genotype
each participant for LMX1A at rs4657412 as described
previously [68]. Specifically, approximately 3ng of gen-
omic DNA will be amplified for LMX1A using the pri-
mer LMX-5': 5'-CTCGCCTCCAGGAATGGGTGTTGTA-3'
and LMX-3': 5'-GCCACGAGGAACTTGTGAGAGGGTT-3',
and under the following conditions: denaturation at 94C
for 5 min, followed by 30 cycles at 94 °C for 30 sec, an-
nealing at 64 °C for 30 sec, and extending at 72 °C for 30
sec. 15 ul of the amplification products will be digested by
2.5U of MslI (R0571s, New England Biolabs, Beverly, MA)
for 2 h at 37°C. The digested PCR products will be then
analyzed on a 4 % agarose gel and visualized using
GelGreen® Nucleic Acid Gel Stain (89139-144, Biotium,
Hayward, CA).
Cerebrospinal fluid cytokines/chemokines and dopamine/
dopamine-related metabolite measurements
Lumbar punctures will be performed at baseline and
1 month after CWMT in participants who have agreed
to spinal taps. The cerebrospinal fluid will be collected,
aliquoted into 0.5 ml portions, and swiftly frozen at
−80 °C. Measurements for both ELISAs and mono-
amines will be run in batches.
ELISA
We will quantify fractalkine, IL-1α, MCP-1, IP-10, IL-8,
and IL-4 using the RayBio ELISA kits (RayBiotech, Inc.,
Norcross, GA, USA). Since fractalkine concentration is
relatively low even in normal serum and plasma, and may
not be detected in the RayBio assay, we plan to use the Hu-
man Fractalkine ELISA kit (ADIPO Bioscience, Inc., Santa
Clara, CA, USA), which is reportedly more sensitive [69].
Cerebrospinal fluid dopamine and dopamine metabolite levels
These will be measured using HPLC assays [70] with
electrochemical detectors and using principal compo-
nent analysis precipitation to remove proteins and
stabilize small molecule analytes. Internal standards will
be used to measure monoamines and their metabolites,
including norepinephrine, dopamine and its metabolites,
3,4-dihydroxyphenylacetic acid and homovanillic acid, as
well as serotonin (5-hydroxytryptamine) and its metabol-
ite, 5-hydroxyindole-3-acetic acid.
Statistical analysis
All analyses will be performed using SAS, using
repeated-measures analysis of variance (ANOVA) as the
primary model (co-varied for age and sex). The baseline
(initial) values of all key variables will be tested for nor-
mality prior to analysis. Appropriate transformations (or
non-parametric tests) will be used as necessary. The
statistical significance will be determined using a modi-
fied Bonferroni procedure for multiple tests [71]. The
procedure will have a type I error probability equal to
0.05 for independent tests.
Neurocognitive assessments will be tested using appro-
priately constructed contrasts within a 2 × 2 repeated-
measures ANOVA model. HIV status (and HAND status
for subgroup analyses) and training condition (adaptive
versus fixed) will be across-subjects variables, and time
(baseline, 1-month, 6-months) will be within-subject vari-
ables. Analyses will be co-varied for subject age, sex, and
other co-variates as needed (e.g., depression scores). Sub-
jects trained in both the adaptive and fixed training will
have the training condition as a within-subject variable.
The fMRI time series will be analyzed using Statistical
Parametric Mapping software (SPM8, Welcome Depart-
ment of Cognitive Neurology, UK). After spatial
normalization and smoothing, maps of brain activation
and differential changes in activation (repeat − baseline)
will be calculated for each subject and task, using a
fixed-effects model with a block design. In a subsequent
random-effects analysis, differences between groups on
BOLD signal changes will be evaluated for each task (t
tests or ANOVA). Statistical significance will be based
on cluster-level significance at P < 0.05 corrected for
multiple comparisons (voxel-level threshold P < 0.05,
cluster size >100 voxels). Additionally, we will extract re-
gional percentage BOLD-fMRI signals from cubic re-
gions of interest (0.729 cm3) centered at cluster maxima,
using a customized program written in MATLAB. The ex-
tracted data will be imported into SAS, where a repeated-
measures ANOVA model will be run to confirm and fur-
ther evaluate the statistical parametric mapping findings.
For the genetic study, we will first determine the
Hardy–Weinberg equilibrium for both allelic and geno-
type frequencies of the LXM1A gene in our cohort. To
minimize the number of correlations, we will use
repeated-measures ANOVA to select cognitive variables
and extracted fMRI data that show changes from base-
line to 6 months after CWMT (adaptive versus active
control). We will assess the relationship of these variables
with the LMX1A genotypes and with cerebrospinal fluid
markers using ANCOVA. Repeated measure ANCOVAs
and multivariate ANCOVAs will also be utilized.
Dissemination plan
At the completion of this trial, we plan to submit several
manuscripts to peer-reviewed journals including;
1. ‘Neural correlates of adaptive working memory
training in HIV patients’: this paper will report on
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the interim findings from the primary outcome
measures, including improvements on working
memory performance and neural efficiencies,
1 month and 6 months after the adaptive version of
CWMT, to assess the gain and maintenance of
working memory improvements after training. Some
of the secondary contrast results, including scoring
on the Behavior Rating Inventory of Executive
Function–Adult Version and LMX1A genotype
effects, will also be reported. These findings may
lead to a larger study to validate whether CWMT
can be used as an adjunctive therapy for HAND.
2. ‘Computerized working memory training in HIV
patients: a double-blind active control study’: this
paper will be written at the completion of subject
enrollments. We will compare the effects of adaptive
versus fixed low level of CWMT on the primary
outcome measures, at 1 month and 6 months after
training compared with baseline assessments. This
will provide further evidence of whether CWMT is
effective for working memory and attention deficits
in HIV patients.
3. This paper will also report on the findings after the
double-blind active control study to evaluate the
efficacy of CWMT on the secondary outcome
measures, including scores on the the Center for
Epidemiological Studies–Depression Scale, Revised,
and the Symptom Checklist–90–revised, and ability
to conduct activities of daily living (Independent
Activity of Daily Living assessment and the Behavior
Rating Inventory of Executive Function–Adult
Version) before and after CWMT.
4. This paper will report on possible improvements in
cerebrospinal fluid neuroinflammatory proteins
(chemokines and cytokines) and neurochemicals
(dopamine and serotonergic levels and their
metabolites) after CWMT. Since only half of the
participants might consent to the lumbar punctures,
we may need to combine results from the adaptive
training group and the fix-low-level training
group to evaluate the training effects on these
cerebrospinal fluid measurements.
We plan to submit our first manuscript on the interim
findings before the end of the project in 2015, and the
other three papers in 2016 or 2017. The findings will
also be presented and discussed at international confer-
ences and workshops, as well as at local symposia to our
community healthcare providers.
Discussion
Cogmed Working Memory Training® may be a useful
adjunctive treatment for HAND in HIV-positive patients
who are receiving combined antiretroviral therapy. Since
CWMT is non-invasive and can be accessed from any
computer via the internet, this safe intervention is easily
accessible and costs less than typical pharmacological
treatments. Furthermore, the proposed work may pro-
vide direct and immediate novel data on the long-term
maintenance effect of adaptive working memory train-
ing, and insight into how the brain and the neural net-
works involved in working memory and attention may
be modified by the training.
The proposed research has several innovative aspects.
(1) We will evaluate a new, non-invasive approach to im-
prove cognitive function in HIV-positive subjects. Except
for a single recent report of a pilot study of ‘internet-based
cognitive stimulation’ (using SmartBrain©) [72], the pro-
posed intervention with CWMT is, to our knowledge, the
first to evaluate whether working memory and other cog-
nitive domains can be improved in HIV patients. (2) This
will, to our knowledge, be the first study to assess neural
plasticity of cognitive training in HIV patients. We will
evaluate the neural correlates of the cognitive improve-
ments associated with the intervention, using fMRI tech-
niques. (3) We will genotype subjects to determine
whether individuals with the TT(AA) alleles for the
LXMI1A gene perform better at working memory training.
This may pave the way for personalized treatments in the
future. (4) Further insights will be derived from studying
the relationships between neuroinflammation and brain
function (correlations among neuropsychological test
scores, working memory performance from the CWMT
program, and cerebrospinal fluid cytokines or chemo-
kines). Our approach will provide unique insights into
how the brain changes after cognitive training. If success-
ful, the study could lead to a larger intervention study to
determine whether working memory training may prevent
or improve behavioral and cognitive problems that affect
HIV-infected patients. Training the brain might be analo-
gous to physical exercise to prevent cardiovascular dis-
eases, and lead to a new era of prevention for brain
disorders.
Expected findings
Gain in working memory performance and transfer of gain
to ‘near’ or ‘far’ transfer tasks (Aim 1)
HIV-positive subjects commonly have working memory
deficits [3, 23–29, 41–43]. Since working memory is
needed to maintain focus on tasks, deficits in working
memory may negatively affect many other cognitive do-
mains, and result in HAND. Prior studies of CWMT
showed that the program enhanced performance not
only on trained working memory tasks, but also on some
non-trained visuospatial and non-trained complex rea-
soning tasks, including executive function [73]. There-
fore, we aim to evaluate the efficacy of CWMT on
cognitive performance in our subjects.
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We hypothesize that all subjects will show improved
working memory after Cogmed® RM training (adaptive
training > low fixed level ‘active control’ training), both
at 1 month and at 6 months after cessation of training.
In addition, not only will adaptive CWMT will lead to
greater improvements than active control training on
the trained tasks, but the gain will transfer to non-
trained tasks that require similar working memory pro-
cesses, including near-transfer tasks (e.g., digit span and
spatial span) and far-transfer tasks (e.g., verbal learning,
logical memory, short-term memory, and recognition
memory). Lastly, we expect that the gain will be greater
in subjects with normal cognition (regardless of HIV sta-
tus) than in those with cognitive deficits (e.g., HAND or
HAND-equivalent).
BOLD-fMRI studies (Aim 2)
BOLD-fMRI has been used to evaluate brain changes in
HIV-positive patients for more than a decade. BOLD-
fMRI signals in these individuals are altered during tasks
that require working memory [74, 75] and visual atten-
tion [74, 76]. A prior study showed that HIV patients
had a lower working memory network capacity, which
was further affected by other concurrent brain activities
(e.g., louder acoustic noise proportionally decreased
working memory activation); hence, they would be dis-
tracted more easily by other activities in their daily life
[75]. Hence, we expect that subjects with normal cogni-
tion (higher working memory capacity) will show greater
improvement than those with cognitive deficits.
BOLD-fMRI signals during working memory tasks were
also greater in cognitively normal HIV-positive subjects
compared with seronegative controls [77], as well as in
HIV-positive subjects receiving antiretroviral medications
compared with both HIV-negative and antiretroviral
medication-naïve subjects and seronegative controls [6].
Greater BOLD-fMRI signals in HIV patients were pre-
dicted by higher levels of glial metabolites (myoinositol,
total creatine, and choline) [78]. These findings suggest
that ongoing increased neuroinflammation in HIV pa-
tients necessitates greater usage of the working memory
network. Such neuroinflammation appeared to be ongoing
despite stable antiretroviral treatments, since HIV-positive
subjects showed increased BOLD-fMRI signals within the
visual attention network in a one-year longitudinal follow-
up study (suggesting decline efficiency), while matched
seronegative controls showed decreased BOLD-fMRI sig-
nals (consistent with a test–retest practice effect) [79].
Therefore, this study will also explore how neuroinflam-
mation as assessed by cerebrospinal fluid inflammatory
markers is related to BOLD-fMRI signals before and after
working memory training.
For this aim, we predict that all subjects will show im-
proved BOLD signals with decreased activation,
indicating greater neural efficiency, in brain networks as-
sociated with working memory (n-back) and visual at-
tention (ball tracking), at 1 month and 6 months after
adaptive working memory training compared with base-
line and relative to active control training. Also, brain
activation will normalize in HIV-positive subjects, who
will show smaller group differences compared with sero-
negative controls at 1 month and even smaller differ-
ences at 6 months after adaptive working memory
training.
Genotype effects (Aim 3)
Since HIV patients have dopaminergic deficits, with de-
creased dopamine transporters [18, 19] and decreased
cerebrospinal fluid dopamine and dopamine metabolites
[62], genetic variations in genes related to dopamine metab-
olism, such as LMX1A or catechol-O-methyltransferase,
may modulate working memory training effects, BOLD-
fMRI results, and cerebrospinal fluid monoamine levels
[55]. For instance, while HIV-positive subjects with the
Met/Met alleles at the catechol-O-methyltransferase Val58-
Met gene (a gene involved in the degradation of released
dopamine) perform better on executive function [80],
healthy individuals with the TT(AA) alleles at the LMX1A-
rs4657412 benefit more from working memory training
than those individuals with the C(G)-carrier [55]. There-
fore, we predict that polymorphism of the LMX1A gene
will differentially affect cognitive improvements among
HIV-positive individuals. Specifically, consistent with a
prior report, we expect that, regardless of HIV serostatus,
subjects with the TT(AA)-alleles at the LMX1A-rs4657412
will perform better on verbal working memory tasks and
have greater training-related gains in verbal working mem-
ory than those carrying the C(G)-allele after CWMT [55],
especially in subjects with normal cognitive function. We
also expect that TT(AA)-carriers will show greater im-
proved neural efficiencies, i.e., greater decreases in BOLD-
fMRI, than TC(AG) or CC(GG) carriers.
Cerebrospinal fluid neuroinflammatory markers and
monoamine metabolites (exploratory aim)
Numerous studies indicate that ongoing aberrant neuro-
inflammation in HIV-infected individuals might contrib-
ute to brain injury associated with HAND [4, 81–83]. In
prior studies, cerebrospinal fluid level of MCP-1 corre-
lated with brain metabolites [84], and the three cerebro-
spinal fluid chemokines (MCP-1, IP-10, and IL-8) had
the strongest correlations with cerebral metabolite pat-
terns [82]. We will measure pro-inflammatory cytokines
(fractalkine, INF-α2, and IL-1α), chemo-attractants
(MCP-1, IP-10, and IL-8) and anti-inflammatory cyto-
kines (IL-4) in the cerebrospinal fluid of our study
participants. We hypothesize that, at baseline, levels of
pro-inflammatory cytokines (fractalkine, INF-α2, and
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IL-1α) and chemo-attractants (MCP-1, IP-10, and IL-8)
will be higher, while the anti-inflammatory cytokine (IL-4)
will be lower in HIV-positive subjects, especially in those
with HAND, compared with seronegative controls. These
markers will correlate with cognitive performance and
BOLD-fMRI signals at baseline more so than at 6 months
after training.
Furthermore, many symptoms of HAND are consistent
with mild Parkinson’s disease; correspondingly, HIV pa-
tients show dopaminergic terminal deficits, with decreased
dopamine transporters [18, 19], and decreased cerebro-
spinal fluid dopamine and dopamine metabolites [62].
Dopamine transporters also correlated with deactivation in
the default mode network on visual attention task [85]. Fur-
thermore, changes in cortical dopamine D1 receptor bind-
ing observed by positron emission tomography were
associated with improvement from CWMT [86]. Therefore,
we expect cerebrospinal fluid monoamine and metabolite
levels to be lower in HIV than in seronegative subjects at
baseline, but levels may increase after CWMT. We also ex-
pect that these levels will correlate with cognitive function
and BOLD-fMRI signals both before and after CWMT.
Additional considerations and future directions
1. Based on our pilot study, individuals with HAND had
the highest dropout rate, probably owing to frustrations
or lack of motivation. Therefore, we will spend more
time to train these participants in our laboratory initially
and coach them during the early phase of the training
(contacting them three or more times per week).
2. We will also ensure that each participant will have a
computer and high-speed internet access (e.g., by
providing internet cards and inexpensive computers,
or by training them in our laboratory, which we
have done successfully during the pilot study). The
training program, CWMT, can be accessed via
internet from any computer.
3. Furthermore, while typical medication trials terminate
clinical contact after the medication phase, we plan to
follow the subjects for 6 months after CWMT; this
allows us to collect novel data on the long-term main-
tenance effect of adaptive working memory training and
determine whether there are any carry-over (positive or
negative) effects of the experimental condition.
4. Lastly, we will collect information regarding physical
exercise and sleep patterns, which could either
enhance or interfere with both baseline cognitive
functioning and their training outcomes [87–89]. As
discussed, cognitive training or stimulation might
be analogous to physical exercise to prevent
cardiovascular diseases, and lead to prevention or
delay development of dementia both in seronegative
and HIV-positive subjects.
The proposed research has significant public health
impact since HAND is an increasing problem with sig-
nificant impact on the lives of afflicted patients and a
growing financial burden to society. The findings from
this protocol may provide foundational information ne-
cessary for the development of a potential adjunctive
non-pharmacological treatment for HAND.
HIV-positive patients with HAND experience difficul-
ties in activities of daily living and negative emotional
well-being. Cognitive deficits and impairment of working
memory are often overlooked, but may in fact be ‘treat-
able’. The data reviewed clearly demonstrate the urgency
of this emerging problem, especially as the HIV-infected
population continues to grow and age. Therefore, our
proposed research has high significance in that the find-
ings may lead to an intervention that might improve the
cognitive function of HIV-infected individuals with
HAND, and possibly delay or prevent the development
of HAND in others.
Trial status
The trial started in September 2012, and is currently
enrolling participants.
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